Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis.

Laura C CappelliClifton O BinghamPatrick M FordeValsamo AnagnostouJulie BrahmerEvan J LipsonJennifer MammenMegan SchollenbergerAmi A ShahErika Darrah

Published in: RMD open (2022)

Anti-RA33 antibodies are present in a subset of patients with ICI-induced IA, absent in other ICI-treated patients and may be a biomarker for developing IA. Additional studies evaluating serial samples before and after ICI treatment will further establish the temporal relationship of these antibodies to IA development.

Keyphrases

rheumatoid arthritis
high glucose
end stage renal disease
diabetic rats
newly diagnosed
ejection fraction
chronic kidney disease
oxidative stress
drug induced
endothelial cells
peritoneal dialysis
prognostic factors
interstitial lung disease
systemic sclerosis
replacement therapy
combination therapy
case control